Results from a new survey are waking Americans up to a widespread health issue – insomnia. Even though 62 percent of Americans regularly suffer from symptoms of insomnia, only 20 percent believe they have the condition and merely 12 percent have been diagnosed by a doctor, according to the America: Insomnia Nation survey supported by Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX).
Insomnia is not just the inability to fall asleep. One of the most illuminating findings from the study was that more than half of Americans are unable to stay asleep through the night.
The ability to get a full uninterrupted night of sleep has many benefits that empower people on a daily basis and is important to well-being, productivity, memory and other vital functions that keep the body going.
The new survey, which sheds light on the nation’s sleep behavior and attitudes toward insomnia and sleeplessness, also uncovered that:
- On average, nearly three-quarters of Americans (72%) are missing out on almost three weeks of sleep per year (470 hours).
- Many Americans (51%) feel that sleeplessness is glamorized and that successful people like CEOs and government or business leaders get less sleep than the average person. However research proves that a good night’s sleep can actually improve performance and spur creativity.
- A good night’s sleep can positively impact mood (74%) and productivity (70%).
- When it comes to health, happiness and wellbeing, Americans rank getting a good night’s sleep second in importance (46%)—just behind spending time with their family (69%).
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market.